Equities Analysts Issue Forecasts for OPKO Health, Inc.’s FY2024 Earnings (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) – Equities researchers at Zacks Research boosted their FY2024 earnings per share (EPS) estimates for shares of OPKO Health in a report issued on Monday, April 15th. Zacks Research analyst I. Bandyopadhyay now expects that the biotechnology company will post earnings per share of ($0.35) for the year, up from their previous forecast of ($0.36). The consensus estimate for OPKO Health’s current full-year earnings is ($0.33) per share. Zacks Research also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, Q1 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.12) EPS.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). The company had revenue of $181.90 million during the quarter, compared to analysts’ expectations of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. OPKO Health’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.11) earnings per share.

OPK has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, April 3rd. Piper Sandler reiterated an “overweight” rating and set a $5.00 target price on shares of OPKO Health in a research report on Monday, April 1st. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. Finally, Barrington Research restated an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a report on Monday, April 1st.

OPKO Health Price Performance

OPKO Health stock opened at $1.25 on Wednesday. The stock has a fifty day moving average of $1.07 and a 200-day moving average of $1.24. The stock has a market capitalization of $871.24 million, a P/E ratio of -5.00 and a beta of 1.82. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. OPKO Health has a 52 week low of $0.85 and a 52 week high of $2.24.

Insider Activity

In other news, Director Richard M. Krasno purchased 30,000 shares of the business’s stock in a transaction on Monday, January 29th. The stock was purchased at an average cost of $0.99 per share, with a total value of $29,700.00. Following the acquisition, the director now directly owns 103,333 shares in the company, valued at $102,299.67. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Phillip Md Et Al Frost purchased 1,000,000 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were acquired at an average price of $0.99 per share, with a total value of $990,000.00. Following the acquisition, the chief executive officer now directly owns 208,368,225 shares in the company, valued at $206,284,542.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard M. Krasno purchased 30,000 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average price of $0.99 per share, with a total value of $29,700.00. Following the completion of the purchase, the director now owns 103,333 shares in the company, valued at $102,299.67. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,630,000 shares of company stock valued at $4,422,700 over the last quarter. Company insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the company. IPG Investment Advisors LLC purchased a new stake in OPKO Health in the 4th quarter worth $30,000. Verition Fund Management LLC purchased a new position in OPKO Health during the 2nd quarter worth $36,000. River Wealth Advisors LLC bought a new stake in shares of OPKO Health in the third quarter valued at about $38,000. Guggenheim Capital LLC bought a new stake in shares of OPKO Health in the 1st quarter valued at about $38,000. Finally, Point72 Hong Kong Ltd purchased a new position in shares of OPKO Health in the 1st quarter valued at $39,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.